8-K: Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Corporation announced its Q1 2025 financial results, highlighted by awaiting FDA action on YUTREPIA, dismissal of a cross-claim by United Therapeutics, full enrollment of Cohort A in the ASCENT study, and strengthened financial position via access of up to $100 million from an existing financing agreement.

Summary

• Liquidia Corporation reported its financial results for the first quarter ended March 31, 2025.
• The company is awaiting FDA action on its New Drug Application (NDA) for YUTREPIA, with a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.
• A cross-claim filed by United Therapeutics challenging the PH-ILD amendment to the YUTREPIA NDA was dismissed by the District Court.
• Cohort A of the ASCENT study, evaluating YUTREPIA in patients with PH-ILD, is fully enrolled with more than 50 patients.
• Liquidia has strengthened its financial position by accessing up to $100 million from its existing financing agreement with HealthCare Royalty Company.
• Cash and cash equivalents totaled $169.8 million as of March 31, 2025, compared to $176.5 million as of December 31, 2024.
• Revenue for the quarter was $3.1 million, compared to $3.0 million for the same period in 2024.
• Research and development expenses decreased to $7.0 million from $10.1 million in the prior year.
• General and administrative expenses increased to $30.1 million from $20.2 million in the prior year.
• Net loss for the quarter was $38.4 million, or $0.45 per share, compared to a net loss of $30.1 million, or $0.40 per share, for the same period in 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are positive developments such as the dismissal of the cross-claim and progress in clinical trials, the increased net loss and rising administrative expenses temper the overall outlook.

Positives

• The District Court dismissed United Therapeutics' cross-claim, removing a potential legal hurdle for YUTREPIA.
• Full enrollment of Cohort A in the ASCENT study indicates progress in evaluating YUTREPIA for PH-ILD.
• Access to additional financing of up to $100 million strengthens Liquidia's financial position and supports commercial development.
• Interim data from the ASCENT study showed patients were able to titrate to doses three-times higher than the labelled target dose of nebulized Tyvaso, while showing positive trends on exploratory measures of efficacy, including 6-minute walk distance.

Negatives

• The company reported a net loss of $38.4 million for the quarter, an increase from the $30.1 million loss in the same period last year.
• General and administrative expenses increased significantly, primarily due to increased personnel expenses related to commercialization preparations.

Risks

• The FDA may not grant final approval for the YUTREPIA NDA, or approval may be delayed.
• United Therapeutics has the right to appeal the District Court's ruling, potentially leading to further legal challenges.
• Clinical trials may not yield positive results, impacting the development of YUTREPIA and L606.
• The company's financial performance is subject to risks discussed in its filings with the SEC.

Future Outlook

Liquidia is focused on preparing for the potential commercial launch of YUTREPIA, pending FDA approval, and continuing the development of YUTREPIA in other clinical trials, including trials for pediatric patients and trials further evaluating the use of YUTREPIA in PAH and PH-ILD patients, clinical development of L606, a sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and for general corporate purposes.

Management Comments

• Dr. Roger Jeffs, Liquidia's Chief Executive Officer, stated that the company remains focused on ensuring they are prepared to make YUTREPIA commercially available as quickly as possible if granted full approval.
• Dr. Jeffs believes that YUTREPIA has the potential to be the prostacyclin of first choice for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Industry Context

Liquidia is operating in the competitive pulmonary hypertension market, with YUTREPIA positioned as a potential alternative to existing treatments like Tyvaso. The dismissal of the cross-claim by United Therapeutics is a positive development, as it removes a potential legal obstacle to YUTREPIA's market entry. The company is also developing L606, a sustained-release formulation of treprostinil, which could provide a competitive advantage.

Comparison to Industry Standards

• Liquidia's YUTREPIA is being developed as an alternative to United Therapeutics' Tyvaso for PAH and PH-ILD.
• The ASCENT study is evaluating the tolerability and titratability of YUTREPIA in PH-ILD patients, with interim data showing patients were able to titrate to doses three-times higher than the labelled target dose of nebulized Tyvaso.
• Liquidia's L606 is a sustained-release formulation of treprostinil, similar to other long-acting formulations in development for pulmonary hypertension.

Stakeholder Impact

• Shareholders are impacted by the financial performance and the progress of YUTREPIA and L606.
• Patients with PAH and PH-ILD could benefit from the potential approval of YUTREPIA and the development of L606.
• Employees are affected by changes in headcount and the shift in activities related to commercialization preparations.

Next Steps

• Awaiting FDA decision on YUTREPIA NDA with a PDUFA goal date of May 24, 2025.
• Presenting additional data from Cohort A of the ASCENT study at the American Thoracic Society (ATS) 2025 International Conference on May 21, 2025.
• Continuing development of YUTREPIA in other clinical trials.
• Continuing clinical development of L606.

Key Dates

Keywords

YUTREPIA, Liquidia, PH-ILD, PAH, Treprostinil, ASCENT study, FDA, Financial Results, L606, Healthcare Royalty